dc.contributor.author | Kleveland, Ola | |
dc.contributor.author | Kunszt, Gabor | |
dc.contributor.author | Bratlie, Marte | |
dc.contributor.author | Ueland, Thor | |
dc.contributor.author | Broch, Kaspar | |
dc.contributor.author | Holte, Espen | |
dc.contributor.author | Michelsen, Annika | |
dc.contributor.author | Bendz, Bjørn | |
dc.contributor.author | Amundsen, Brage H. | |
dc.contributor.author | Espevik, Terje | |
dc.contributor.author | Aakhus, Svend | |
dc.contributor.author | Damås, Jan Kristian | |
dc.contributor.author | Aukrust, Pål | |
dc.contributor.author | Wiseth, Rune | |
dc.contributor.author | Gullestad, Lars | |
dc.date.accessioned | 2018-01-08T08:51:33Z | |
dc.date.available | 2018-01-08T08:51:33Z | |
dc.date.created | 2016-08-17T14:24:30Z | |
dc.date.issued | 2016 | |
dc.identifier.citation | European Heart Journal. 2016, 37 (30), 2406-2413. | nb_NO |
dc.identifier.issn | 0195-668X | |
dc.identifier.uri | http://hdl.handle.net/11250/2476113 | |
dc.description.abstract | Aims
Interleukin-6 (IL-6) contributes to atherosclerotic plaque destabilization and is involved in myocardial injury during ischaemia–reperfusion. Interleukin-6 is therefore a potential therapeutic target in myocardial infarction (MI). We hypothesized that the IL-6 receptor antagonist tocilizumab would attenuate inflammation, and secondarily reduce troponin T (TnT) release in non-ST-elevation MI (NSTEMI).
Methods and results
In a two-centre, double-blind, placebo-controlled trial, 117 patients with NSTEMI were randomized at a median of 2 days after symptom onset to receive placebo (n = 59) or tocilizumab (n = 58), administered as a single dose prior to coronary angiography. High sensitivity (hs) C-reactive protein and hsTnT were measured at seven consecutive timepoints between Days 1 and 3. The area under the curve (AUC) for high-sensitivity C-reactive protein was the primary endpoint. The median AUC for high-sensitivity C-reactive protein during hospitalization was 2.1 times higher in the placebo than in the tocilizumab group (4.2 vs. 2.0 mg/L/h, P < 0.001). Also, the median AUC for hsTnT during hospitalization was 1.5 times higher in the placebo group compared with the tocilizumab group (234 vs. 159 ng/L/h, P = 0.007). The differences between the two treatment groups were observed mainly in (i) patients included ≤2 days from symptom onset and (ii) patients treated with percutaneous coronary intervention (PCI). No safety issues in the tocilizumab group were detected during 6 months of follow-up.
Conclusion
Tocilizumab attenuated the inflammatory response and primarily PCI-related TnT release in NSTEMI patients. | nb_NO |
dc.language.iso | eng | nb_NO |
dc.publisher | Oxford University Press (OUP) | nb_NO |
dc.title | Effect of a single dose of the interleukin-6 receptor antagonist tocilizumab on inflammation and troponin T release in patients with non-ST-elevation myocardial infarction: a double-blind, randomized, placebo-controlled phase 2 trial | nb_NO |
dc.type | Journal article | nb_NO |
dc.type | Peer reviewed | nb_NO |
dc.description.version | publishedVersion | nb_NO |
dc.source.pagenumber | 2406-2413 | nb_NO |
dc.source.volume | 37 | nb_NO |
dc.source.journal | European Heart Journal | nb_NO |
dc.source.issue | 30 | nb_NO |
dc.identifier.doi | 10.1093/eurheartj/ehw171 | |
dc.identifier.cristin | 1373530 | |
dc.relation.project | Norges forskningsråd: 223255 | nb_NO |
dc.description.localcode | Published by Oxford University Press on behalf of the European Society of Cardiology. All rights reserved. © The Author(s) 2016. | nb_NO |
cristin.unitcode | 194,65,25,0 | |
cristin.unitcode | 194,65,15,0 | |
cristin.unitname | Institutt for sirkulasjon og bildediagnostikk | |
cristin.unitname | Institutt for klinisk og molekylær medisin | |
cristin.ispublished | true | |
cristin.fulltext | original | |
cristin.qualitycode | 2 | |